Tackling the Toughest Issues and Cases of Hypertriglyceridemia: Web Activity
Release date: December 28, 2012
Expiration date: December 31, 2013
Estimated time to complete activity: 1.0 hour
Course viewing requirements:
PC: Internet Explorer (v6 or greater), Google Chrome, or Firefox
MAC: Safari or Firefox
Jointly sponsored by Postgraduate Institute for Medicine (www.pimed.com) and MedtelligenceTM.
This activity is supported by an educational grant from Amarin Corporation plc.
This activity has been designed to meet the educational needs of Clinical Cardiologists, Lipidologists, Endocrinologists, Internists, Hospitalists, Nurse Practitioners, Physician Assistants, Nurses, Registered Dieticians, Fellows, and other healthcare professionals involved in the care of patients with cardiovascular disease, elevated triglycerides, diabetes, and CV-associated comorbidities.
This online activity is based on Tackling the Toughest Issues and Cases of Hypertriglyceridemia: Experts Conference Bowl held on November 5, 2012. Selected faculty presentations (audio and slides) include:
After completing this activity, the participant should be better able to:
Sergio Fazio, MD, PhD, is the Cornelius Vanderbilt Chair of Cardiovascular Medicine, Professor of Medicine and of Pathology, Immunology and Microbiology, and Chief of the Section of Cardiovascular Disease Prevention at Vanderbilt University Medical Center in Nashville, Tennessee. He earned his medical degree, completed residency in internal medicine, and was a clinical fellow in metabolic diseases at the University of Rome in Italy. Dr. Fazio holds a doctorate in experimental medicine from the University of Siena in Italy, and completed his research training at the University of California in San Francisco. His clinical interest is in the management of patients with dyslipidemia. He participates in clinical trials and is involved in the determination of new mutations that cause altered lipid levels in humans. Dr. Fazio’s research interests are focused on the pathogenesis of genetic dyslipidemias, the early cellular events of atherogenesis, and gene therapy approaches to atherosclerosis. He is a principal investigator on several studies sponsored by the National Institutes of Health, is a fellow of the American Society for Clinical Investigation and the Association of American Physicians, and is on the editorial board for Circulation Research, ATVB, and the Journal of Clinical Lipidology.
JoAnne M. Foody, MD, is the Medical Director of the Cardiovascular Wellness Program at Brigham and Women’s Hospital and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts. She earned her medical degree from the University of Chicago Pritzker School of Medicine, completed her internship and a residency in internal medicine at Brigham and Women’s Hospital, and held a fellowship in cardiology at the Cleveland Clinic Foundation. Dr. Foody’s research focuses on identifying and fostering greater use of clinical strategies that prevent adverse cardiovascular events in people with and without coronary artery disease. She has had leadership roles on the National AMI and National Heart Failure projects of the Centers for Medicare & Medicaid Services. A Fellow of the American College of Cardiology and the American Heart Association, Dr. Foody is editor of the authoritative text Preventive Cardiology and serves as Editor in Chief of CardioSmart.org, the ACC’s patient website.
Allen J. Taylor, MD, is Chief of the Cardiology Division, Department of Medicine, at Georgetown University in Washington, DC. He earned his medical degree from The Johns Hopkins University School of Medicine, completed his residency in internal medicine at the Walter Reed Army Medical Center, and conducted fellowships in cardiovascular diseases (University of Virginia) and medical research (Walter Reed Army Institute of Research). Dr. Taylor’s major research accomplishments include defining the role of lipid lowering therapy on carotid atherosclerosis, focusing on HDL cholesterol and the use of niacin. His pioneering work in the field of cardiac CT includes conducting long-term prospective outcomes trials, randomized clinical trials on the utility of the technique, and methods to enhance the safety and appropriateness of cardiovascular imaging. He has published numerous manuscripts in the areas of imaging, lipids, prevention, cardiovascular outcomes, and quality in journals such as Circulation, JAMA, and the New England Journal of Medicine.
Physician Continuing Education
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Medtelligence, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Sergio Fazio, MD, PhD: Consulting Fees: Amarin Corporation plc, Hoffman-La Roche Inc., Kowa Pharmaceuticals America, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi US; Contracted Research: Isis Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc.
JoAnne M. Foody, MD: Consulting Fees: Amarin Corporation plc, Bristol-Meyers Squibb, Merck & Co., Inc., Pfizer Inc.
Allen J. Taylor, MD: Fees for non-CME/CE services: Abbott Laboratories
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Medtelligence, LLC: Ben Caref, PhD, and Pamela Clark hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period December 28, 2012 through December 31, 2013, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu under course links, click on “Find Evaluation/Post-test” and then enter Course number 9273. Upon registering and successfully completing the post-test with a score of 60% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Amarin, and Medtelligence, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Amarin, and Medtelligence, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.